Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.57 |
| ▸ | CTSS | P25774 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CCR6 | P51684 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | CCNK | O75909 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3477124 | 0.98 | CTSK (0.60) | CTSKCTSSEPHX1NPC1RAB9A | |
| SCHEMBL15739641 | 0.96 | CTSK (0.54) | CTSKCTSSEPHX1NPC1RAB9A | |
| SCHEMBL12733191 | 0.92 | CCR6 (0.49) | CTSKCTSSEPHX1NPC1RAB9A | |
| SCHEMBL377685 | 0.85 | CTSS (0.48) | CTSKCTSSEPHX1TRPA1CCR6 | |
| Hydrochloric Acid SCHEMBL23302911 | 0.83 | CTSS (0.47) | CTSKCTSSEPHX1TRPA1CCR6 | |
| Hydrochloric Acid SCHEMBL383062 | 0.83 | CTSS (0.47) | CTSKCTSSEPHX1TRPA1CCR6 | |
| SCHEMBL13450562 | 0.83 | CCR6 (0.47) | CTSKCTSSEPHX1NPC1RAB9A | |
| SCHEMBL16480090 | 0.83 | CCR6 (0.47) | CTSKCTSSEPHX1NPC1RAB9A | |
| SCHEMBL3816119 | 0.83 | IRAK4 (0.51) | CTSKCTSSEPHX1TRPA1CCR6 | |
| SCHEMBL7790085 | 0.83 | TRPA1 (0.47) | CTSKCTSSEPHX1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110313158-A1 | Two Component Recyclable Heterogeneous Catalyst, Process for Preparation Thereof and its Use for Preparation of Amines | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-12-22 | — | — | US | claimed |
| WO-2010097815-A2 | A TWO COMPONENT RECYCLABLE HETEROGENEOUS CATALYST, PROCESS FOR PREPARATION THEREOF AND ITS USE FOR PREPARATION OF AMINES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-09-02 | — | — | WO | claimed |
| US-11168062-B2 | Compounds for the treatment of Clostridium difficile infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210340117-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210340116-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-11-04 | — | — | US | disclosed |
| US-20190210984-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2019-07-11 | — | — | US | disclosed |
| EP-2506716-B1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20110313158-A1 | Two Component Recyclable Heterogeneous Catalyst, Process for Preparation Thereof and its Use for Preparation of Amines | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-12-22 | — | — | US | disclosed |
| WO-2010097815-A2 | A TWO COMPONENT RECYCLABLE HETEROGENEOUS CATALYST, PROCESS FOR PREPARATION THEREOF AND ITS USE FOR PREPARATION OF AMINES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313158-A1 | Two Component Recyclable Heterogeneous Catalyst, Process for Preparation Thereof and its Use for Preparation of Amines | HCN2, RAC2, HCN1 | CTSK 2119/4885CTSS 1237/4885EPHX1 636/4885 |
| US-20190210984-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | VNN1, NGLY1, NUCB2 | CTSK 3317/4885CTSS 2228/4885EPHX1 2241/4885 |
| US-11168062-B2 | Compounds for the treatment of Clostridium difficile infection | VNN1, NGLY1, NUCB2 | CTSK 3317/4885CTSS 2228/4885EPHX1 2241/4885 |
| US-20210340117-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | VNN1, NGLY1, NUCB2 | CTSK 3317/4885CTSS 2228/4885EPHX1 2241/4885 |
| US-20210340116-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | VNN1, NGLY1, NUCB2 | CTSK 3317/4885CTSS 2228/4885EPHX1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.